Pharma Focus Asia

Revvity Announces New Licence Agreement with AstraZeneca

Thursday, May 18, 2023

Revvity announced a new licence agreement with AstraZeneca for the technology underlying its Pin-point™ base editing system, a next-generation modular gene editing platform with a strong safety profile.

This non-exclusive agreement with AstraZeneca will support the creation of cell therapies for the treatment of cancer and immune-mediated diseases. The fundamental goal of the Pin-point platform is to translate the technology from pre-clinical research into the clinic, and ultimately, impact patient lives.

The Pin-point system and the underlying base editing technology is designed to enable highly efficient and precise single and multiplex (multi-gene) editing without unintended impact on cell viability or functionality. 

Compared to traditional CRISPR technologies, which create double-stranded breaks in the DNA, this newer editing system uses a modified Cas enzyme that only nicks one strand of the DNA. This allows for a more controlled approach to gene disruption and base correction.

The Pin-point base editing system is part of Revvity’s cell and gene therapy portfolio which spans gene modulation and editing, cell analysis, immunoassays, and optimised AAV and lentiviral vector development and manufacturing to improve the specificity, efficacy and safety of cell and gene therapies.
 

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024